Category: Perspective

Title: COVID-19 in Africa: What else?

Authors: Philippe Parola \(^{1,2}\) *, Souleymane Brah\(^3\), Abdoulaye Djimde\(^4\), Nadjet Mouffok\(^5\), Majida Zahraoui\(^6\), Ali Ould Mohamed Salem Boukhary\(^7\), Idir Bitam\(^2,8\), Mahamadou Ali Thera\(^4\), Jean-Bernard Lekana-Douki\(^9\), Eric Adehossi\(^9\), Moussa Seydi\(^10\), Jean-Christophe Lagier\(^1,11\), Jaafar Heikel\(^6\), Didier Raoult\(^1,1\) , Cheikh Sokhna\(^2,12\)

Affiliations:

1 University Hospital Institute *IHU-Méditerranée Infection*, Marseille, France
1 Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France
2 Service de Médecine Interne, Hôpital Général de Référence, Niamey, Niger
3 Malaria Research and Training Center, University of Science, Techniques and Technologies of Bamako, Bamako, Mali
4 Service des Maladies Infectieuses, Centre Hospitalier Universitaire, Oran, Algeria
5 Service de Médecine Interne, Clinique De Vinci, Casablanca, Morocco
6 Université de Nouakchott Al Aasriya, Nouakchott, Mauritania
7 Ecole Supérieure en Sciences de l'Aliment et des Industries Agroalimentaire, Direction générale de la recherche scientifique et développement technologique, Ministère de l'enseignement supérieur et de la recherche scientifique, Alger, Algeria
8 Département de Parasitologie-Mycologie, Université des Sciences de la Santé (USS) Libreville, UNEEREP-CIRMF, Franceville, Gabon.
9 Université Abdou Moumouni, Niger
10 Service de Maladies Infectieuses et Tropicale, Centre Hospitalier Universitaire de Fann, Université Cheikh Anta Diop, Dakar, Senegal.
Corresponding Author:

Philippe Parola

Email: philippe.parola@univ-amu.fr

Phone: +33413732401

Keywords: COVID-19, SARS-Cov2, hydroxychloroquine, azithromycin, Africa
Perspective:

The factors which may explain the dampened course of COVID-19 in Africa, have been recent recently discussed in Science, from genetic characteristics to immunological factors and even microbiote (1). However, a major issue is missing. Indeed, after the first Chinese publications about antiviral effects of chloroquine (CQ) and its derivatives against SARS-COV2 (2,3) and a preliminary trial in France (4), many African countries have adopted CQ or hydroxychloroquine (HCQ) with or without azithromycin (AZ) to treat presumptive or confirmed COVID-19 cases (5,6). And this, despite the WHO position (7) and published studies claiming that this regimen would not be effective (8,9). More evidence came with the demonstration of a synergistic effect of in vitro HCQ-AZ combination on SARS-CoV-2 at concentrations compatible with that obtained in the human lung (10) and from observational studies with thousands of treated cases (11). In addition, both HCQ and AZ are immunomodulators, which may prevent the “cytokine storm” of COVID 19 (12, 13). In the context of pulmonary embolism associated with covid, it is important to highlight that in vitro and animal models have demonstrated that HCQ had several antithrombotic effects (14, 15). Also, several clinical studies have underlined the interest of HCQ for thrombosis prevention in antiphospholipid syndrome of interest in the context of COVID-19 induces coagulopathy (16, 17, 18). Finally, AZ-HCQ has been associated with a reduction in viral shedding, with potential public health effects by reducing the duration of contagiousness (4,11).

The use of HCQ-AZ remains controversial and has resulted in political issues and academic discord (19-23). Randomized controlled trial (RCT) are not relevant for urgent health issues such as emerging infectious disease outbreaks (24). While in many African countries a pragmatic safely use of CQ or HCQ with or without AZ has prevailed, Western countries are still awaiting the results of clinical trials to define their strategy, worrying about hypothetical side effects of HCQ-AZ that have been used for decades, or are favoring other treatments (with no
demonstration of efficacy) or the standard care only, which may be limited when people are asked
to stay home.

We, being Professors of Infectious diseases or microbiology, MD, PhD, coauthors from Algeria,
Morocco, Senegal, Niger, Mali, Mauritania, Gabon, and France (with teams working in Africa),
all involved in the COVID 19 pandemic in Africa, have attempt to submit a letter to Science in
reply to the article of Mbow et al. (1), to comment their article and discuss the potential role of the
large use of chloroquine derivative with or without azithromycin in many African countries,
including ours. The paper was rejected the day after submission. We are unsure if the rejection
was as stated because its “scope and focus make it more appropriate for a more specialized
journal”, or in relation with the political position of Science (19-23), any conflict of interest of the
journal editors, or any other reason. However, we think that to understand and comment the
situation in Africa, it deserves credit to hear African scientists and doctors. To date, the countries
with the highest mortality from COVID-19 include the countries that have demonized CQ, HCQ
or HCQ-AZ the most, i.e. Western Europe and part of the United States (5, 6). Although the link
between the large cost-effective use of CQ, HCQ or HCQ-AZ and the evolution of the COVID-19
pandemic in Africa has not been demonstrated, it deserves to be discussed.
Conflict of Interest and Financial Disclosures:

No authors have financial or non-financial actual or potential conflicts of interest.
References:


5. Roussel Y, Raoult D. Hydroxychloroquine recommendations toward the world: first evaluations. Submitted. Pre-print DOI: https://doi.org/10.35088/wjzn-1×68


label non-randomized clinical trial: response to David Spencer (Elsevier) Submitted. Pre-print doi: https://doi.org/10.35088/bjjr-cy47